Lack of a Clinically Meaningful Drug Interaction Between the HIV-1 Antiretroviral Agents Islatravir, Dolutegravir, and Tenofovir Disoproxil Fumarate

Deanne Jackson Rudd¹, Saijuan Zhang¹, Kerry L. Fillgrove¹, Sabrina Fox-Bosetti¹, Randolph P. Matthews¹, Evan Friedman¹, Danielle Armas², S. Aubrey Stoch¹, and Marian Iwamoto¹

Abstract
Islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor, is in clinical development for the treatment and prevention of HIV-1 infection. Because islatravir may be coadministered with other antiretroviral agents, assessment of potential drug-drug interactions are warranted. This phase 1, open-label, fixed-sequence, 2-period trial in adults without HIV (N = 12) assessed the safety and pharmacokinetic interactions of islatravir administered with dolutegravir and tenofovir disoproxil fumarate (TDF). In period 1, participants received a single oral dose of islatravir (20 mg). In period 2, participants received oral doses of dolutegravir (50 mg) and TDF (300 mg) once daily on days 1 through 11, with a single oral dose of islatravir (20 mg) coadministered on day 8. There were no clinically significant changes in islatravir, dolutegravir, or TDF pharmacokinetics following coadministration. Islatravir was generally well tolerated when administered alone or in combination with dolutegravir and TDF. Coadministration of islatravir, dolutegravir, and TDF is supported, with no clinically meaningful effect on pharmacokinetics, safety, or tolerability in participants without HIV.

Keywords
clinical pharmacology, clinical trials, drug-drug interactions, HIV/AIDS, pharmacokinetics and drug metabolism

The morbidity and mortality associated with HIV-1 infection have been dramatically reduced with the advent of combination antiretroviral therapy,¹ and HIV-1 can now be managed as a chronic disease in which individuals can anticipate a near-normal life expectancy.¹,² Combination antiretroviral therapy typically involves the coadministration of therapeutic agents from different drug classes to suppress HIV-1 replication.³ Despite the number of effective agents and combination regimens, current treatments are associated with limitations, such as adverse events and development of drug resistance.³,⁴ As such, development of new and improved antiretroviral agents is warranted, including those that allow for alternative dosing schedules. Moreover, antiretrovirals with a low risk for drug interactions are warranted given the increasing need for polypharmacy among the aging population of people living with HIV-1.⁵

Islatravir is an investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI) in clinical development for the treatment and prevention of HIV-1 infection.⁶,⁷ Islatravir is rapidly converted by endogenous intracellular kinases to its pharmacologically active triphosphate form, which has demonstrated high

¹Merck & Co., Inc., Kenilworth, New Jersey, USA
²Celerion, Tempe, Arizona, USA

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Submitted for publication 10 December 2020; accepted 30 August 2021.

Corresponding Author:
Deanne Jackson Rudd, PhD, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033
(e-mail: deanne_rudd@merck.com)
potency against HIV-1 and a long intracellular half-life that allows for use of varying dosing schedules, from once daily to more extended durations. In vitro, islatravir inhibits multiple strains of HIV-1, including common nucleoside reverse transcriptase inhibitor (NRTI)-resistant variants, and may have a high barrier to the development of resistance. Investigations determined limited drug-drug interactions of islatravir with no inhibitory effect on cytochrome p450 (CYP) biotransformation isoforms CYP1A2, 2B6, 2C8, 2C9, 2C19, and 2D6 at concentrations up to 100 μM and CYP3A4 up to 200 μM. No inhibitory effects were observed on uridine diphosphate glucuronosyltransferase 1A1 at concentrations up to 100 μM. Islatravir was not found to interfere with commonly associated drug transporters, pumps, transfer proteins, extrusion proteins, or resistance proteins and also displayed low levels of plasma protein binding. Existing evidence suggests that islatravir is unlikely to interact with major metabolic and transport pathways associated with commonly coprescribed medications.

When administered orally as a single dose as low as 0.5 mg, islatravir demonstrated effective viral suppression for up to 7 days in treatment-naive adults with HIV-1. In adults without HIV, single oral doses of islatravir were rapidly absorbed, reaching peak plasma concentrations at ~0.5 hours, with a plasma half-life of ~49 to 61 hours. Intracellular islatravir triphosphate levels peaked between 6 and 24 hours and demonstrated a half-life of ~118 to 171 hours. The pharmacokinetic profile of islatravir was comparable in individuals with and those without HIV-1. Islatravir has also been generally well tolerated across all clinical trials conducted to date.

Islatravir is being evaluated in combination with doravirine, a nonnucleoside reverse transcriptase inhibitor, as a once-daily oral regimen for the treatment of HIV-1. A phase 2b clinical trial demonstrated that islatravir in combination with doravirine was generally well tolerated and maintained virologic suppression for up to 48 weeks in treatment-naive adults with HIV-1; participants switched to the 2-drug combination following initiation on a 3-drug regimen of islatravir, doravirine, and lamivudine after 24 weeks. A comprehensive phase 3 clinical trial program to investigate the treatment potential of islatravir and doravirine across populations of people living with HIV-1 will also include a trial in heavily treatment-experienced individuals who are failing their current antiretroviral therapy regimen, in which islatravir and doravirine will be coadministered in combination with optimized background antiretroviral therapy (NCT04233216). Because islatravir may be coadministered with other antiretroviral agents, assessment of the drug interaction with commonly used agents is warranted.

Dolutegravir, an integrase strand transfer inhibitor, and tenofovir disoproxil fumarate (TDF), an NRTI, are commonly used in combination and have no significant drug interactions with each other. Dolutegravir-based regimens are among the preferred first-line regimens recommended in HIV-1 treatment guidelines. Peak fasting plasma concentrations of dolutegravir are observed 0.5 to 1.25 hours following oral administration, with steady-state concentrations achieved within ~5 days following once-daily multiple dosing. Peak plasma concentrations of tenofovir, the pharmacologically active form of TDF, are observed ~1 hour after oral administration of TDF, with steady-state concentrations achieved within ~7 days following once-daily dosing.

A clinical trial was conducted to assess the safety and pharmacokinetic interaction between islatravir and the combination of dolutegravir and TDF in adult participants without HIV.

Methods

Investigational Review Board
The trial protocol, protocol amendment, and informed consent forms were approved by the Chesapeake Research Review (Columbia, Maryland) institutional review board. Before initiation of the trial, participants provided written informed consent to the procedures of the trial, with acknowledgment of the potential risks. The trial was conducted at Celeron (Tempe, Arizona) in conformance with Good Clinical Practice and following applicable local requirements regarding ethical committee review, informed consent, and other statutes or regulations regarding the protection of the rights and welfare of humans participating in biomedical research.

Trial Design
This was a phase 1, open-label, fixed-sequence, 2-period trial in adults without HIV (protocol MK-8591-005). In period 1, participants received a single oral dose of 20 mg islatravir. In period 2, participants received multiple oral doses of 50 mg dolutegravir and 300 mg TDF once daily for 11 consecutive days (days 1-11), with a single oral dose of 20 mg islatravir coadministered on day 8. There was a washout period of ≥7 days between islatravir dosing in period 1 and the first dose of dolutegravir and TDF in period 2 (Figure 1).

Dose selection for islatravir in this trial was based on preliminary data obtained from a monotherapy efficacy trial in treatment-naive adults with HIV-1. Based on a pharmacokinetic threshold that is projected to achieve intracellular concentrations of active islatravir triphosphate at efficacious levels, a dose of 20 mg islatravir was selected. A dose of 20 mg is anticipated to represent the upper range for treatment with weekly dosing and achieves islatravir triphosphate levels similar to those...
achieved at steady state with 0.75 mg daily dosing. For dolutegravir and TDF, the dose selected is the current US Food and Drug Administration–approved marketed dose as per labeling.

**Participants**
Eligible participants were male or female adults aged 18 to 55 years, of nonchildbearing potential, and with a body mass index of 19 to 32 kg/m². Key exclusion criteria included preexisting health conditions determined by the investigator to be clinically significant; infection with HIV, hepatitis B virus, or hepatitis C virus; nicotine or illicit drug use; creatinine clearance <80 mL/min; or an inability to refrain from the use of any medication, including prescription and nonprescription and herbal remedies.

**Assessments**

**Pharmacokinetics.** Blood samples for islatravir plasma analysis were collected before dosing and at selected time points over 96 hours following administration of islatravir on day 1 of period 1 and day 8 of period 2. In period 2, samples taken at 24, 48, and 72 hours for islatravir plasma analysis were collected before dose administration of dolutegravir and TDF. Blood samples for plasma analysis of dolutegravir and tenofovir were collected before dosing on days 1, 7, and 8 of period 2 and at selected time points over 24 hours after dosing on days 7 and 8 of period 2. The 24 hour samples for dolutegravir and tenofovir analysis for days 7 and 8 were collected before dosing of dolutegravir and TDF.

The following pharmacokinetic parameters were assessed as appropriate for each drug: area under the plasma concentration–time curve from 0 to infinity (AUC<sub>0-∞</sub>), area under the plasma concentration–time curve over the last 24-hour dosing interval (AUC<sub>0-24</sub>), maximum observed plasma concentration (C<sub>max</sub>), plasma concentration at 24 hours after dosing (C<sub>24</sub>), time to reach C<sub>max</sub> (t<sub>max</sub>), and apparent terminal half-life (t<sub>1/2</sub>).

Plasma concentrations of islatravir, dolutegravir, and tenofovir were determined by inVentiv Health Clinique (Québec City, Québec, Canada) using validated high-performance liquid chromatography coupled to tandem mass spectrometry methods. All values below the lower limit of quantitation were treated as 0.

Islatravir (m/z 294.000/154.000) was extracted using an automated protein precipitation method using [13C,15N₃]-ISL as internal standard (m/z 297.800/158.000). The extracted samples were assessed on a system equipped with a X Select HSS T3 C18, 50×2.1 mm, 2.5 μm column with water/acetonitrile with formic acid mobile phase. Over the calibration range, intraday precision and accuracy ranged from 3.38% to 4.21% coefficient of variation (CV) and 101.23% to 104.57%, respectively. Interday precision and accuracy ranged from 1.20% to 4.61% CV and 87.79% to 106.87%, respectively. The lower limit of quantitation for islatravir was 0.10 ng/mL, with an analytical range of 0.10 to 100.00 ng/mL.

Dolutegravir (m/z 420.200/277.200) was extracted using an automated protein precipitation method using [13C₃-d₃]-dolutegravir as the internal standard.
The extracted samples were assessed on a system equipped with an ACE 3 C18, 30 × 4.6 mm, 3 μm column (Avantor, Radnor, Pennsylvania) with water/methanol with ammonium formate and formic acid mobile phase. Over the calibration range, intraday precision and accuracy ranged from 0.91% to 2.50% CV and 99.44% to 103.82%, respectively. Interday precision and accuracy ranged from 0.16% to 19.80% CV and 99.96% to 109.18%, respectively. The lower limit of quantitation for dolutegravir was 10.00 ng/mL, with an analytical range of 10.00 to 10 000.00 ng/mL.

Tenofovir (m/z 288.200/176.200) was extracted using an automated solid phase extraction using tenofovir-d6 as internal standard (m/z 294.100/182.300). The extracted samples were assessed on a system equipped with an Atlantis dC18, 75 × 4.6 mm, 3 μm column (Waters Corp., Milford, Massachusetts) with water/acetonitrile with ammonium formate and formic acid mobile phase. Over the calibration range, intraday precision and accuracy ranged from 0.79% to 3.40% CV and 97.69% to 99.18%, respectively. Interday precision and accuracy ranged from 1.06% to 3.22% CV and 98.35% to 102.38%, respectively. The lower limit of quantitation for tenofovir was 0.50 ng/mL, with an analytical range of 0.50 to 500.00 ng/mL.

Safety and Tolerability. Safety and tolerability were monitored by repeated clinical and laboratory evaluations for the duration of the trial. Safety evaluations included adverse event (AE) reports, laboratory tests, 12-lead electrocardiograms, and vital signs.

Statistical Analyses

Pharmacokinetics. Plasma islatravir, dolutegravir, and tenofovir pharmacokinetics were summarized descriptively. Pharmacokinetic parameter values were calculated using the software Phoenix WinNonlin version 6.3 (Certara, Princeton, New Jersey). Cmax, C24, and tmax values were obtained directly from the observed plasma concentration–time data. AUC0-inf and AUC0-24 were calculated using the linear trapezoidal method for ascending concentrations and the log trapezoidal method for descending concentrations (linear-up/log-down). The apparent terminal half-life was calculated as the quotient of the natural log(ln) of 2 and λz (ln[2]/λz), where λz was the apparent first-order terminal elimination rate constant calculated from the slope of the linear regression of the terminal log-linear portion of the plasma concentration–time profile.

Individual AUC0-inf and Cmax values for plasma islatravir were natural log-transformed before analysis and evaluated separately using a linear mixed-effects model with a fixed-effect term for treatment. An unstructured covariance matrix was used to allow for unequal treatment variances and to model the correlation between the treatment measurements within each participant. Kenward and Roger’s method was used to calculate the denominator degrees of freedom for the fixed effects. Two-sided 90% confidence intervals (CIs) were constructed for the difference in least-squares means on the log scale for AUC0-inf and Cmax. Exponentiating the 90%CI on the log scale, 90%CIs for the geometric least-squares mean ratios (islatravir plus dolutegravir plus TDF/islatravir alone) were provided for the AUC0-inf and Cmax.

Individual AUC0-24, Cmax, and C24 of dolutegravir and tenofovir were natural log-transformed and analyzed separately using the same model described for islatravir analysis, with the point estimates and the corresponding 90%CIs for geometric least-squares mean ratios provided.

Safety and Tolerability. Incidence of adverse experiences was descriptively summarized.

Results

Participants
A total of 12 participants were enrolled in and completed both periods of the trial. Participant demographics are summarized in Table 1.

Pharmacokinetics

Plasma Pharmacokinetic Analysis for Islatravir. Coadministration of islatravir with steady-state dolutegravir and TDF increased islatravir AUC0-inf by 28% with comparable Cmax, tmax, and apparent terminal t1/2 values compared with islatravir administered alone (Table 2 and Figure 2A).
Table 2. Summary of Plasma Pharmacokinetics of Islatravir After a Single Dose of 20 mg Islatravir With or Without Coadministration of Multiple Doses of 50 mg Dolutegravir and 300 mg TDF to Men and Women Without HIV

| Pharmacokinetic Parameter | Islatravir Alone | Islatravir + Dolutegravir + TDF | Islatravir + Dolutegravir + TDF / Islatravir Alone |
|---------------------------|------------------|-------------------------------|-----------------------------------------------|
|                           | AM (SD)          | GM (95%CI)                    | AMR (SD)                                      |
| AUC<sub>0-inf</sub>, μg × h<sup>1/2</sup> | 2.00 (0.353)   | 1.97 (1.77-2.19)             | 2.53 (0.319)                                  |
| C<sub>max</sub>, μM<sup>1/2</sup> | 0.495 (0.135)  | 0.479 (0.403-0.568)          | 0.522 (0.114)                                 |
| t<sub>max</sub>, h<sup>1/2</sup>   | 0.75 (0.50-3.01)| 1.00 (0.50-2.01)             | 1.10 (0.30)                                  |
| Apparent terminal         | 57.2 (8.4)      | 56.6 (15.1)                  | 56.2 (5.8)                                   |
| t<sub>1/2</sub>, h<sup>1/2</sup> | 56.2 (5.8)      | 55.9 (10.4)                  | 56.2 (5.8)                                   |

AM, arithmetic mean; AMR, arithmetic mean ratio; AUC<sub>0-inf</sub>, area under the plasma concentration–time curve from time 0 to infinity; CI, confidence interval; C<sub>max</sub>, maximum observed plasma concentration; CV, coefficient of variation; GM, geometric least-squares mean; GMR, geometric least-squares mean ratio; SD, standard deviation; t<sub>1/2</sub>, half-life; TDF, tenofovir disoproxil fumarate; t<sub>max</sub>, time to reach maximum observed plasma concentration.

a Single dose of 20 mg islatravir administered on day 1 in period 1.
b Multiple oral once-daily doses of 50 mg dolutegravir and 300 mg TDF coadministered on days 1 through 11 with a single oral dose of 20 mg islatravir on day 8 in period 2.
c Within-participant CV (%) estimated based on the elements of the variance-covariance matrix: CV (%) = 100 × sqrt[(s<sub>A</sub><sup>2</sup> + s<sub>B</sub><sup>2</sup> - 2 × s<sub>AB</sub>)/2].
d Back-transformed least-squares means and CIs from linear mixed-effects model performed on natural log-transformed values.
e Median (min-max) reported for t<sub>max</sub>.
f Geometric mean and geometric CV (%) is reported for apparent terminal t<sub>1/2</sub>.
g 1 μM of islatravir is equivalent to 293 ng/mL.

Plasma Pharmacokinetic Analysis for Dolutegravir and Tenofovir. Coadministration of multiple once-daily oral doses of dolutegravir and TDF with a single oral dose of islatravir resulted in comparable steady-state dolutegravir (Table 3 and Figure 2B) and tenofovir (Table 4 and Figure 2C) pharmacokinetics compared with administration without islatravir.

Safety and Tolerability

Administration of islatravir alone and in combination with dolutegravir and TDF was generally well tolerated. In total, 6 of 12 participants reported AEs, of whom 5 reported AEs considered to be drug-related: 3 participants after administration of islatravir; 3 participants after administration of dolutegravir and TDF; and 1 participant after coadministration of all 3 therapies. All AEs were mild or moderate in intensity and resolved by the end of the study.

The most common drug-related AE was headache, reported by 3 participants, while all other drug-related AEs—abdominal discomfort, constipation, nausea, chest discomfort, viral infection, back pain, dysgeusia, and alopecia—were each reported by 1 participant.

No deaths or serious AEs occurred, and no participants discontinued because of an AE. No clinically meaningful treatment-related changes were observed in laboratory, vital signs, or electrocardiogram safety parameter values.

Discussion

Islatravir is a novel NRTTI that has shown potential to be efficacious in the treatment and prevention of HIV-1 infection. This trial was conducted to investigate the potential impact of coadministration of islatravir with dolutegravir and TDF on the pharmacokinetic and safety profile of these agents. The trial results demonstrated no clinically meaningful pharmacokinetic drug-drug interactions, with no safety issues identified with coadministration.

New treatment options are needed to meet the diverse needs of people living with HIV, including heavily treatment-experienced individuals who have exhausted all or nearly all antiretroviral therapies as a result of extensive multidrug resistance or intolerance. Islatravir has the potential to be the first NRTTI for the treatment and prevention of HIV-1 infection. It is essential, therefore, to fully establish the pharmacologic and clinical profile of islatravir, including when islatravir is used in combination with other antiretrovirals, to meet such needs. The combination of islatravir and doravirine is currently being investigated not only in treatment-naive and treatment-experienced individuals...
Figure 2. Arithmetic mean plasma concentration–time profiles. (A) Islatravir: following single-dose administration of 20 mg islatravir with and without multiple doses of 50 mg dolutegravir and 300 mg TDF administered once daily for 8 days to men and women without HIV (N = 12). Inset, semilog scale; 1 nM of islatravir is equivalent to 0.293 ng/mL. (B) Dolutegravir: following multiple-dose administration of 50 mg dolutegravir and 300 mg TDF once daily dosed to steady state (7 days) with and without a single dose of 20 mg islatravir to men and women without HIV (N = 12). Inset, semilog scale. (C) Tenofovir: following multiple-dose administration of 50 mg dolutegravir and 300 mg TDF once daily dosed to steady state (7 days) with and without a single dose of 20 mg islatravir to men and women without HIV (N = 12). Inset, semilog scale. TDF, tenofovir disoproxil fumarate; TFV, tenofovir.

but also in heavily treatment-experienced people living with HIV-1. Preclinical studies have demonstrated that islatravir has high potency against HIV-1 and NRTI-resistant variants, with the potential to have a high barrier to the development of resistance,26 while doravirine has been shown to be effective against common nonnucleoside reverse transcriptase inhibitor–resistant HIV-1 variants.27,28 The favorable pharmacokinetics and drug-interaction profiles of islatravir coadministered with doravirine,25 doravirine coadministered with
Table 3. Summary of Plasma Pharmacokinetics of Dolutegravir After Administration of Multiple Oral Daily Doses of 50 mg Dolutegravir and 300 mg TDF With and Without a Single Oral Dose of 20 mg Islatravir to Men and Women Without HIV

| Pharmacokinetic Parameter | Dolutegravir + TDF | Islatravir + Dolutegravir + TDF | Islatravir + Dolutegravir + TDF / Dolutegravir + TDF |
|---------------------------|-------------------|-------------------------------|-------------------------------------------------------|
| N = 12                    | N = 12            |                               |                                                       |
| AUC_{0-24}, ng × h/mL     | AM (SD) 51 200 (19 100) | GM (95%CI) 48 000 (37 900-60 900) | AM (SD) 54 300 (16 900) | GM (95%CI) 52 000 (42 700-63 200) | AMR (SD) 1.09 (0.12) | GMR (90%CI) 1.08 (1.02-1.14) | Within-Participant CV, % 7.5 |
| C_{max}, ng/mL            | AM (SD) 3720 (1350) | GM (95%CI) 3500 (2770-4430) | AM (SD) 3720 (1080) | GM (95%CI) 3570 (2950-4330) | AMR (SD) 1.03 (0.17) | GMR (90%CI) 1.02 (0.94-1.11) | 11.5 |
| C_{24}, ng/mL             | AM (SD) 1220 (502) | GM (95%CI) 1120 (861-1470) | AM (SD) 1310 (476) | GM (95%CI) 1240 (990-1550) | AMR (SD) 1.11 (0.14) | GMR (90%CI) 1.10 (1.03-1.17) | 8.6 |
| t_{max}, h                | AM (SD) 2.50 (0.50-4.13) | GM (95%CI) 3.00 (1.00-6.03) | AM (SD) 2.50 (0.50-4.13) | GM (95%CI) 3.00 (1.00-6.03) | AMR (SD) 2.50 (0.50-4.13) | GMR (90%CI) 3.00 (1.00-6.03) | 11.5 |
| Apparent terminal         | AMR 15.3 (2.1) | GMR 15.2 (1.4) | AMR 15.7 (2.7) | GMR 15.5 (1.6) | AMR 15.3 (2.1) | GMR 15.2 (1.4) | 11.5 |
| t_{1/2}, h                | AM (SD) 1.95 (1.2) | GM (95%CI) 1.93 (1.1) | AM (SD) 1.95 (1.2) | GM (95%CI) 1.93 (1.1) | AMR (SD) 1.95 (1.2) | GMR (90%CI) 1.93 (1.1) | 11.5 |

AM, arithmetic mean; AMR, arithmetic mean ratio; AUC_{0-24}, area under the plasma concentration–time curve over the last 24-hour dosing interval; C_{max}, maximum observed plasma concentration; CV, coefficient of variation; GM, geometric least-squares mean; GMR, geometric least-squares mean ratio; SD, standard deviation; t_{1/2}, half-life; TDF, tenofovir disoproxil fumarate; t_{max}, time to reach maximum observed plasma concentration.

*Multiple oral once-daily doses of 50 mg dolutegravir and 300 mg TDF administered on days 1 through 7 in period 2.

†Multiple oral once-daily doses of 50 mg dolutegravir and 300 mg TDF administered on days 1 through 11 coadministered with a single oral dose of 20 mg islatravir on day 8 in period 2.

‡Within-participant CV (%) estimated on the basis of the elements of the variance-covariance matrix: CV (%) = 100 × sqrt[(s^2_A + s^2_B - 2 × s_{AB})/2].

§Back-transformed least-squares means and CIs from linear mixed-effects model performed on natural log-transformed values.

¶Median (min-max) reported for t_{max}.

#Geometric mean and geometric CV (%) is reported for apparent terminal t_{1/2}.

dolutegravir, and doravirine coadministered with TDF, and the similar pharmacokinetics of islatravir in individuals living with and without HIV-1 have already been established. The findings demonstrated in this study add support to the further investigation of adding a combination of islatravir and doravirine to optimized background antiretroviral therapy comprising dolutegravir and TDF in heavily treatment-experienced people living with HIV-1.

The pharmacokinetic findings of this study were expected based on the known metabolic pathways of each antiretroviral agent. Dolutegravir is hepatically metabolized by uridine diphosphate glucuronosyltransferases and CYP3A4 and does not induce or inhibit CYP enzymes or uridine diphosphate glucuronosyltransferase 1A1 at physiologic concentrations. TDF is metabolized by plasma and tissue esterases to tenofovir, which is then phosphorylated intracellularly to the active form, tenofovir diphosphate. Tenofovir is not metabolized by CYP enzymes, nor does it induce or inhibit these enzymes. Tenofovir is renally eliminated as unchanged drug by glomerular filtration and active tubular secretion. Islatravir is eliminated enzymatically primarily by adenosine deaminase–mediated metabolism and is not expected to have significant drug-drug interactions. No clinically meaningful drug-drug interactions were demonstrated following coadministration of islatravir with doravirine. Furthermore, no significant drug-drug interactions have been observed following coadministration of islatravir with levonorgestrel and/or ethinyl estradiol, common components of hormonal contraceptives.

A potential limitation of this trial is that only a single dose of islatravir was administered during each treatment period. However, given what is known about islatravir, dolutegravir, and tenofovir, islatravir is not anticipated to affect the pharmacokinetics of either drug regardless of dose or number of doses. Dolutegravir and TDF were administered in multiple doses to achieve near-maximum induction potential and were dosed for an additional 3 days after islatravir dosing to maintain enzyme inhibition through the islatravir pharmacokinetic collection period. Another limitation of the trial is the use of a fixed-sequence vs randomized crossover design selection, which may have led to a period effect. Owing to the operational complexity of the crossover design, the fixed-sequence approach was selected, with the expectation that a period effect would not significantly impact the results.
Table 4. Summary of Plasma Pharmacokinetics of Tenofovir After Administration of Multiple Oral Daily Doses of 50 mg Dolutegravir and 300 mg TDF With and Without a Single Oral Dose of 20 mg Islatravir to Men and Women Without HIV

| Pharmacokinetic Parameter | Dolutegravir + TDF<sup>a</sup> | Islatravir + Dolutegravir + TDF<sup>b</sup> | Islatravir + Dolutegravir + TDF / Dolutegravir + TDF |
|---------------------------|-------------------------------|--------------------------------|---------------------------------------------|
|                           | N = 12                         | N = 12                          | AMR (SD) | GMR (90% CI) | Within-Participant CV, % |
| AUC<sub>0-24</sub>, ng × h/mL<sup>e</sup> | 2250 (377)                     | 2350 (332) | 1.06 (0.19) | 0.96-1.14 | 11.4 |
| C<sub>max</sub>, ng/mL<sup>e</sup> | 346 (65.9)                     | 343 (83.8) | 1.00 (0.23) | 0.88-1.10 | 15.5 |
| C<sub>24</sub>, ng/mL<sup>d</sup> | 43.6 (9.53)                    | 45.3 (7.63) | 1.06 (0.17) | 0.97-1.14 | 10.9 |
| t<sub>max</sub>, h<sup>f</sup> | 1.00 (0.50-1.01)               | 1.01 (0.51-2.01)               |        |              | |
| Apparent terminal        |                               |                                |        |              | |
| t<sub>1/2</sub>, h<sup>f</sup> | 13.8 (1.6)                    | 13.3 (1.4) | 13.2 (1.1) |              | |

AM, arithmetic mean; AMR, arithmetic mean ratio; AUC<sub>0-24</sub>, area under the plasma concentration–time curve over the last 24-hour dosing interval; C<sub>max</sub>, maximum observed plasma concentration; CV, coefficient of variation; GM, geometric least-squares mean; GMR, geometric least-squares mean ratio; SD, standard deviation; t<sub>1/2</sub>, half-life; TDF, tenofovir disoproxil fumarate; t<sub>max</sub>, time to reach maximum observed plasma concentration.

<sup>a</sup> Multiple oral once-daily doses of 50 mg dolutegravir and 300 mg TDF on days 1 through 7 in period 2.
<sup>b</sup> Multiple oral once-daily doses of 50 mg dolutegravir and 300 mg TDF on days 1 through 11 coadministered with a single oral dose of 20 mg islatravir on day 8 in period 2.
<sup>c</sup> Within-participant CV (%) estimated based on the elements of the variance-covariance matrix: CV (%) = 100 × sqrt[(s<sup>2</sup><sub>A</sub> + s<sup>2</sup><sub>B</sub> -2 × s<sub>AB</sub>)/2].
<sup>d</sup> Back-transformed least-squares means and CIs from linear mixed-effects model performed on natural log-transformed values.
<sup>e</sup> Median (min-max) reported for t<sub>max</sub>.
<sup>f</sup> Geometric mean and geometric CV (%) is reported for apparent terminal t<sub>1/2</sub>.

Conclusions
The coadministration of islatravir with dolutegravir and TDF revealed no clinically meaningful impact on islatravir, dolutegravir, and tenofovir pharmacokinetics, with no safety issues identified. These data support continued clinical investigation of islatravir as an option for the treatment and prevention of HIV-1 infection.

Acknowledgments
The authors thank the participants and clinical research staff who took part in this study. Medical writing and editorial assistance, under the direction of the authors, were provided by Philippa Cates, PhD, ApotheCom (UK) in accordance with Good Publication Practice guidelines. This assistance was funded by MSD.

Conflicts of Interest
D.J.R., S.Z., K.L.F., S.F.B., R.P.M., E.F., S.A.S., and M.I. are current or former employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey, and may have stock options in Merck & Co., Inc.

Funding
Funding for this research was provided by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey (MSD).

Data-Sharing Statement
The data-sharing policy for Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey, including restrictions, is available at http://engagezone.msd.com/ds documentation.php. Requests for access to the clinical study data can be submitted through the EngageZone site or via email to dataaccess@merck.com.

References
1. Rodger AJ, Lodwick R, Schechter M, et al. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS. 2013;27(6):973-979.
2. Lohse N, Obel N. Update of survival for persons with HIV infection in Denmark. Ann Intern Med. 2016;165(10):749-750.
3. Arts EJ, Hazuda DJ. HIV-1 antiretroviral drug therapy. *Cold Spring Harb Perspect Med.* 2012;4(4):a007161.

4. O’Brien ME, Clark RA, Besch CL, Myers L, Kissinger P. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. *J Acquir Immune Defic Syndr.* 2003;34(4):407-414.

5. Ware D, Palella FJ Jr., Chew KW, et al. Prevalence and trends of polypharmacy among HIV-positive and -negative men in the Multicenter AIDS Cohort Study from 2004 to 2016. *PLoS One.* 2018;13(9):e0203890.

6. Markowitz M, Grobler JA. Islatravir for the treatment and prevention of infection with the human immunodeficiency virus type 1. *Curr Opin HIV AIDS.* 2020;15(1):27-32.

7. Markowitz M, Sarafianos SG. 4′-Ethynyl-2-fluoro-2′-deoxyadenosine, MK-8591: a novel HIV-1 reverse transcriptase translocation inhibitor. *Curr Opin HIV AIDS.* 2018;13(4):294-299.

8. Grobler J, Lai M-T, Barrett SE, et al. Long-acting oral and parenteral dosing of MK-8591 for HIV treatment or prophylaxis. Conference on Retroviruses and Opportunistic Infections (CROI); February 22–25, 2016; Boston, MA.

9. Nakata H, Amano M, Koh Y, et al. Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4′-ethyl-2-fluoro-2′-deoxyadenosine. *Antimicrob Agents Chemother.* 2007;51(8):2701-2708.

10. Michailidis E, Marchand B, Kodama EN, et al. Mechanism of inhibition of HIV-1 reverse transcriptase by 4′-ethyl-2-fluoro-2′-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor. *J Biol Chem.* 2009;284(51):35681-35691.

11. Maeda K, Desai DV, Aoki M, Nakata H, Kodama EN, Mitsuya H. Delayed emergence of HIV-1 variants resistant to 4′-ethyl-2-fluoro-2′-deoxyadenosine: comparative sequential passage study with lamivudine, tenofovir, emtricitabine and BMS-986001. *Antivir Ther.* 2014;19(2):179-189.

12. Bleasby K, Houle R, Hafey M, et al. Islatravir is not expected to be a victim or perpetrator of drug-drug interactions via major drug-metabolizing enzymes or transporters. *Viruses.* 2021;13:1566.

13. Schürmann D, Rudd DJ, Zhang S, et al. Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial. *Lancet HIV.* 2020;7(3):e164-e172.

14. Rudd D, Cao Y, Vaddady P, et al. Modeling-supported islatravir dose selection for phase 3. Poster presented at Conference on Retroviruses and Opportunistic Infections (CROI); March 8–10, 2020; Boston, MA.

15. Matthews RP, Rudd JD, Levine V, et al. Multiple daily doses of MK-8591 as low as 0.25 mg are expected to suppress HIV. Oral presentation at Conference on Retroviruses and Opportunistic Infections (CROI); March 4–7, 2018; Boston, MA.

16. Matthews RP, Ankrom W, Friedman E, et al. Safety, tolerability, and pharmacokinetics of single- and multiple-dose administration of islatravir (MK-8591) in adults without HIV. *Clin Transl Sci.* 2021;14:1935-1944.

17. Molina JM, Yazdanpanah Y, Afani Saud A, et al. MK-8591 at doses of 0.25 to 2.25 mg QD, in combination with doravirine establishes and maintains viral suppression through 48 weeks in treatment-naive adults with HIV-1 infection. 10th International AIDS Society Conference on HIV Science (IAS); July 21–24, 2019; Mexico City, Mexico, 2019.

18. Song I, Min SS, Borland J, et al. Lack of interaction between the HIV integrase inhibitor S/GSK1349572 and tenofovir in healthy subjects. *J Acquir Immune Defic Syndr.* 2010;55(3):365-367.

19. Gunthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 Recommendations of the International Antiretroviral Therapy-USA Panel. *JAMA.* 2016;316(2):191-210.

20. Min S, Song I, Borland J, et al. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. *Antimicrob Agents Chemother.* 2010;54(1):254-258.

21. Barditch-Crovo P, Deeks SG, Collier A, et al. Phase II/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. *Antimicrob Agents Chemother.* 2001;45(10):2733-2739.

22. Markowitz M, Zolopa A, Squires K, et al. Phase II/I study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new pro-drug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults. *J Antimicrob Chemother.* 2014;69(5):1362-1369.

23. Matthews RP, Schürmann D, Jackson Rudd D, et al. Single doses as low as 0.5 mg of the novel NRTTI MK-8591 suppress HIV for at least seven days. 9th IAS Conference on HIV Science; July 23–26, 2017; Paris, France, 2017.

24. Matthews RP, Barrett SE, Patel P, et al. First-in-human trial of MK-8591-eluting implants demonstrates concentrations suitable for HIV prophylaxis for at least one year. 10th International AIDS Society Conference on HIV Science (IAS); July 21–24; 2019; Mexico City, Mexico.

25. Aves T, Tambe J, Siemieniuk RA, Mbaagbaw L. Antiretroviral resistance testing in HIV-positive people. *Cochrane Database Syst Rev.* 2018;11:CD006495.
26. Grobler J, Huang Q, Hazuda DJ, Lai M-T. Efficacy of MK-8591 against diverse HIV-1 subtypes and NRTI-resistant clinical isolates. HIV Glasgow 2018, October 28-31, 2018; Glasgow, UK. J Intern AIDS Soc. 2018;21:e25187. https://doi.org/10.1002/jia2.25187

27. Lai MT, Feng M, Falgueyret JP, et al. In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother. 2014;58(3):1652-1663.

28. Feng M, Wang D, Grobler JA, Hazuda DJ, Miller MD, Lai MT. In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways. Antimicrob Agents Chemother. 2015;59(1):590-598.

29. Matthews RP, Jackson Rudd D, Fillgrove KL, et al. No difference in MK-8591 and doravirine pharmacokinetics after co-administration. IDWeek 2018; October 3-7, 2018; San Francisco, CA.

30. Anderson MS, Khalilieh S, Yee KL, et al. A two-way steady-state pharmacokinetic interaction study of doravirine (MK-1439) and dolutegravir. Clin Pharmacokinet. 2017;56(6):661-669.

31. Anderson MS, Gilmartin J, Fan L, et al. No meaningful drug interactions with doravirine, lamivudine and tenofovir disoproxil fumarate coadministration. Antivir Ther. 2019;24(6):443-450.

32. Reese MJ, Savina PM, Generaux GT, et al. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos. 2013;41(2):353-361.

33. Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet. 2004;43(9):595-612.

34. Kirby KA, Michailidis E, Fetterly TL, et al. Effects of substitutions at the 4′ and 2 positions on the bioactivity of 4′-ethynyl-2-fluoro-2′-deoxyadenosine. Antimicrob Agents Chemother. 2013;57(12):6254-6264.

35. Ankrom W, Jonathan D, Jackson Rudd D, et al. MK-8591 does not alter the pharmacokinetics of the oral contraceptives levonorgestrel and ethinyl estradiol. IDWeek 2018; October 3-7, 2018; San Francisco, CA.